Diabetic Macular Edema
📧 Sign up to get email alerts when something new happens for Diabetic Macular Edema.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2026-02-27Clinical Trial Update: A Study Conducted to Evaluate the Conjunctiva and Tenon's Capsule Status of Healthy Subjects and in Participants With Neovascular Age-related Macular Degeneration (nAMD)/Diabetic Macular Edema (DME)
This clinical trial update notes the completion of a study evaluating the conjunctiva and Tenon's capsule status in healthy subjects and in …
-
CLINICAL_TRIALS research · 2026-02-13Clinical Trial Update: Observational Study of Adult Participants With Diabetic Macular Edema and Suboptimal Response to Anti-Vascular Endothelial Growth Factor Treated With Dexamethasone Intravitreal Implant
An observational study update examining adults with diabetic macular edema who have suboptimal response to anti-VEGF therapy and are treated…
-
CLINICAL_TRIALS research · 2026-02-12Clinical Trial Update: Real World Evidence in China: Faricimab Use in Diabetic Macular Edema, Retinal Vein Occlusion, and Neovascular Age-Related Macular Degeneration (The Farseeing Study)
This clinical trial update describes a real-world evidence study evaluating the use of faricimab in diabetic macular edema, neovascular age-…
-
CLINICAL_TRIALS research · 2026-02-06Clinical Trial Update: Association Between Dry Eye Disease and Diabetic Macular Edema
A clinical trial is exploring the association between dry eye disease and diabetic macular edema. The study is not yet recruiting.
-
CLINICAL_TRIALS trial_result · 2026-01-27Clinical Trial Update: Study of INV-102 Ophthalmic Solution in Adults With Diabetic Macular Edema Associated With Non-proliferative Diabetic Retinopathy [Phase 2]
A Phase 2 trial evaluating INV-102 Ophthalmic Solution in adults with diabetic macular edema associated with non-proliferative diabetic reti…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
EMA approval · 2026-01-19EMA Authorised: Opuviz (aflibercept) — Samsung Bioepis NL B.V.
EMA authorised Opuviz (aflibercept) by Samsung Bioepis NL B.V. for treating several retinal conditions including wet age-related macular deg…
-
CLINICAL_TRIALS trial_result · 2026-01-13Clinical Trial Update: A Pivotal Safety and Efficacy Study of OCS-01 Eye Drops in Participants With Diabetic Macular Edema (DIAMOND 2) [Phase 3]
This is a Phase 3 pivotal safety and efficacy study of OCS-01 Eye Drops for diabetic macular edema, with the DIAMOND 2 trial currently liste…
-
CLINICAL_TRIALS research · 2026-01-13Clinical Trial Update: Comparison of Bevacizumab and Aflibercept in Treatment of Diabetic Macular Edema [NA]
Clinical trial update comparing bevacizumab versus aflibercept for diabetic macular edema is currently enrolling by invitation at CMH Multan…
-
CLINICAL_TRIALS other · 2026-01-13Clinical Trial Update: A Pivotal Safety and Efficacy Study of OCS-01 Eye Drops in Participants With Diabetic Macular Edema (DIAMOND 1) [Phase 2, Phase 3]
Status update on the DIAMOND 1 pivotal safety and efficacy study of OCS-01 Eye Drops for diabetic macular edema, with the trial currently in…
-
EMA approval · 2026-01-09EMA Authorised: Rimmyrah (ranibizumab) — Qilu Pharma Spain S.L.
EMA authorised Rimmyrah (ranibizumab) for several ocular indications including wet age-related macular degeneration and macular edema; decis…
-
CLINICAL_TRIALS research · 2026-01-09Clinical Trial Update: An Assistant Model for Anti-VEGF Therapy Decision [NA]
This document reports a clinical trial update about an assistant model designed to aid decision-making for anti-VEGF therapy in retinal dise…
-
EMA approval · 2026-01-06EMA Authorised: Vabysmo (Faricimab) — Roche Registration GmbH
The EMA authorised Vabysmo (faricimab) by Roche Registration GmbH for treatment of wet age-related macular degeneration, macular edema, and …
-
CLINICAL_TRIALS research · 2026-01-06Clinical Trial Update: A Study of 2 Doses of EYE103 Compared With Ranibizumab (0.5 mg) in Participants With DME [Phase 2, Phase 3]
A clinical trial update comparing two doses of EYE103 with ranibizumab (0.5 mg) in people with diabetic macular edema; the Phase 2/Phase 3 s…
-
CLINICAL_TRIALS research · 2025-12-30Clinical Trial Update: Wide Field OCTA in Ocular Diseases
Clinical trial update on a wide-field optical coherence tomography angiography (OCTA) study across several ocular diseases, sponsored by IRC…
-
CLINICAL_TRIALS research · 2025-12-24Clinical Trial Update: Comparing Single Versus Multiple Anti-VEGF Injections in Diabetic Patients Undergoing Cataract Surgery [Phase 4]
Phase 4 clinical trial comparing single versus multiple anti-VEGF injections in diabetic patients undergoing cataract surgery; currently not…
-
CLINICAL_TRIALS research · 2025-12-22Clinical Trial Update: Micropulse Laser in Treatment of Initial and Refractory Cases of Center-Involved Diabetic Macular Edema
This clinical trial listing describes a recruiting study evaluating micropulse laser therapy for center-involved diabetic macular edema, inc…
-
CLINICAL_TRIALS research · 2025-12-11Clinical Trial Update: Evaluation of Tonabersat for DME [Phase 2]
An active Phase 2 clinical trial is evaluating tonabersat for diabetic macular edema, currently not recruiting.
-
EMA approval · 2025-12-10EMA Authorised: Eydenzelt (aflibercept) — Celltrion Healthcare Hungary Kft.
EMA authorised Eydenzelt (aflibercept) from Celltrion Healthcare Hungary Kft. for multiple ocular conditions including wet age-related macul…
-
CLINICAL_TRIALS research · 2025-12-05Clinical Trial Update: Micropulse Laser Photocoagulation in Diabetic Macular Edema [NA]
This clinical trial update notes that the NCT07266597 study investigating micropulse laser photocoagulation for diabetic macular edema is no…
-
CLINICAL_TRIALS research · 2025-12-03Clinical Trial Update: Phase I Study to Assess the Safety and Efficacy of OCU200 for Center-Involved Diabetic Macular Edema (DME) [Phase 1]
Phase I clinical trial evaluating the safety and efficacy of OCU200 for center-involved diabetic macular edema, currently recruiting.
-
CLINICAL_TRIALS trial_result · 2025-12-01Clinical Trial Update: Observational Study to Evaluate Fluid Resolution and Effectiveness in Patients Receiving Beovu in Neovascular Age-related Macular Degeneration and Visual Impairment Due to Diabetic Macular Edema
This completed observational study assesses fluid resolution and the overall effectiveness of Beovu (brolucizumab) in patients with neovascu…
-
EMA approval · 2025-11-21EMA Authorised: Eiyzey (aflibercept) — Zaklady FarmaFarmaceutyczne Polpharma S.Aceutyczne Polpharma S.A.
The EMA authorised Eiyzey (aflibercept) from Zaklady Farmaceutyczne Polpharma S.A. for multiple retinal diseases, including wet age-related …
-
CLINICAL_TRIALS research · 2025-11-21Clinical Trial Update: Evaluation of Serum- and OCT Biomarkers in Patients With DME Treated With Anti-VEGF or Dexamethasone Implant [NA]
A clinical trial registry entry describes a study evaluating serum- and OCT biomarkers in patients with diabetic macular edema treated with …
-
CLINICAL_TRIALS trial_result · 2025-11-20Clinical Trial Update: A 2-part Study Consisting of Multiple Ascending Dose (MAD) Safety Study, and a Dose-finding Masked Study to Assess the Safety and Efficacy of Intravitreal (IVT) EYE103 in Patients With Diabetic Macular Edema (DME) or Neovascular Age-related Macular Degeneration (NVAMD) [Phase 1, Phase 2]
Two-part Phase 1/2 trial evaluating intravitreal Eye103 for safety and efficacy in diabetic macular edema and neovascular age-related macula…
-
FDA approval · 2025-11-19FDA Approved: EYLEA HD — Supplemental Application (Regeneron Pharmaceuticals, Inc)
The FDA approved a supplemental application for EYLEA HD (aflibercept) by Regeneron, introducing a high-dose formulation.